The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck squamous cell carcinoma undergoing radiotherapy with contraindications to ...

Adagrasib plus cetuximab sustained clinical efficacy in KRAS G12C–mutant unresectable or metastatic colorectal cancer with longer follow-up, according to the KRYSTAL-1 trial. Longer-term follow-up ...

Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival We performed a single-institution retrospective analysis of patients with R/M HNSCC treated ...

Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Penile Cancer. According to GlobalData, Phase I drugs for Penile Cancer does ...

NEW YORK, February 04, 2025 -- ( BUSINESS WIRE )--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

Adding cetuximab (C) to postoperative radiotherapy (RT) improves disease-free survival (DFS) but not overall survival (OS) in intermediate-risk squamous cell carcinoma of the head and neck.

Tesla stock dropped in the DeepSeek sell off, but nothing like Nvidia stock. Deutsche Bank, however, believes investors ...